Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD

Thorax

Volumn 60, Issue 11, 2005, Pages 916-924

  Aliverti, A ^a,b   Rodger, K ^b   Dellaca R L ^a   Stevenson, N ^b   Lo Mauro, A ^a   Pedotti, A ^a   Calverley, P M A ^b  

^a POLITECNICO DI MILANO   (Italy)

^b University Hospital Aintree   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SALBUTAMOL;

ABDOMINAL WALL MUSCULATURE; AGE DISTRIBUTION; AGED; ARTICLE; BREATHING EXERCISE; BREATHING PATTERN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSPNEA; EXERCISE TEST; EXPIRATORY FLOW; EXPIRATORY RESERVE VOLUME; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; INSPIRATORY CAPACITY; LUNG FUNCTION TEST; LUNG VOLUME; MALE; MEDICAL NEBULIZER; METABOLIC RATE; NON INVASIVE MEASUREMENT; OXYGEN CONCENTRATION; OXYGEN CONSUMPTION; PHOTOELECTRIC PLETHYSMOGRAPHY; PHYSICAL STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; SAMPLE SIZE; SITTING; THORAX WALL;

AGED; ALBUTEROL; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; EXERCISE; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG VOLUME MEASUREMENTS; MALE; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VITAL CAPACITY;

EID: 27744480192     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2004.037937     Document Type: Article

References (27)

1. Anon. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl I):1-232.
2. Aliverti A, Stevenson N, Dellacà RL, et al. Regional chest wall volumes during exercise in chronic obstructive pulmonary disease. Thorax 2004;59:210-6.
3. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001;56:880-7.
4. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease (review). N Engl J Med, 2004;24, 350:2689-97.
5. Hay JG, Stone P, Carter J, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992;5:659-64.
6. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40.
7. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542-9.
8. O'Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004;24:86-94.
9. Man WD, Mustfa N, Nikoletou D, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004;59:471-6.
10. Duranti R, Filippelli M, Bianchi R, et al. Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD. Chest 2002;122:2009-14.
11. British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997;52(Suppl 5):S1-28.
12. American Thoracic Society. ATS Statement. Snowbird Workshop on Standardization of Spirometry. Am Rev Respir Dis 1979:831-8.
13. Cala SJ, Kenyon CM, Ferrigno G, et al. Chest wall and lung volume estimation by optical reflectance motion analysis. J Appl Physiol 1996;81:2680-9.
14. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-81.
15. Liesker JJ, Wijkstra PJ, Ten Hacken NH, et al. Systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest 2002;121:597-608.
16. Iscoe S. Control of abdominal muscles (review). Prog Neurobiol 1998;56:433-506.
17. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1256-76.
18. Hadcroft J, Calverley PM. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax 2001;56:713-20.
19. Iandelli I, Aliverti A, Kayser B, et al. Determinants of exercise performance in normal men with externally imposed expiratory flow-limitation. J Appl Physiol 2002;92:1943-52.
20. Aliverti A, landelli I, Duranti R, et al. Respiratory muscle dynamics and control during exercise with externally imposed expiratory flow-limitation. J Appl Physiol 2002;92:1953-63.
21. Stark-Leyva, Kristy N, Ken C Beck, et al. Johnson. Influence of expiratory loading and hyperinflation on cardiac output during exercise. J Appl Physiol 2004;96:1920-7.
22. 2 during cycling exercise in COPD patients. J Appl Physiol 2001;90:1013-9.
23. Montes de Oca M, Rassulo J, Celli BR. Respiratory muscle and cardiopulmonary function during exercise in very severe COPD. Am J Respir Crit Care Med 1996;154:1284-9.
24. Polkey MI, Kyroussis D, Hamnegard CH, et al. Diaphragm performance during maximal voluntary ventilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;155:642-8.
25. Dellacà RL, Santus P, Aliverti A, et al. Detection of expiratory flow limitation in COPD using the forced oscillation technique. Eur Respir J 2004;23:232-40.
26. Kayser B, Sliwinski S, Yan S, et al. Respiratory effort sensation during exercise with induced expiratory flow limitation in healthy humans. J Appl Physiol 1997;83:936-47.
27. Vathenen AS, Britton JR, Ebden P, et al. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988;138:850-5.